Navepegritide for the treatment of hypochondroplasia
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Navepegritide (Primary)
- Indications Hypochondroplasia
- Focus Therapeutic Use
- 16 Jan 2025 New trial record
- 12 Jan 2025 According to an Ascendis Pharma media release, company is planning to submit IND or similar application for the treatment of hypochondroplasia in the fourth quarter of 2025.